Are Peptides FDA Approved, Compounded, or Research Use Only?

This is the post that most peptide content skips. The regulatory status of a peptide determines its safety accountability, quality standards, and the legal framework for its use. Most patients searching for peptide therapy do not know the difference between an FDA-approved drug, a compounded preparation, and a research-use-only chemical. That knowledge gap is where harm happens.

This post exists because media coverage of peptide gray markets, contamination incidents, and unapproved compound use has increased significantly in recent years. Understanding the regulatory categories is not a bureaucratic exercise. It is how patients protect themselves. This connects to the BPC-157 post BPC-157: What It Is, What People Claim, and What Evidence Actually Exists and the red flags post 7 Red Flags When Buying Peptides Online.

The Three Categories

FDA-Approved Peptides

These are drugs that have completed FDA review: randomized controlled trials establishing efficacy, Good Manufacturing Practice (GMP) standards ensuring purity and consistency, and post-market surveillance for safety signals.

Examples:

• Semaglutide (Ozempic, Wegovy): A GLP-1 agonist approved for type 2 diabetes and obesity management
• Tirzepatide (Mounjaro, Zepbound): A dual GIP/GLP-1 agonist approved for the same categories
• Bremelanotide (Vyleesi): PT-141, approved for hypoactive sexual desire disorder in premenopausal women
• Tesamorelin (Egrifta): A growth hormone-releasing factor approved for HIV-associated lipodystrophy
• Leuprolide, goserelin: GnRH agonists approved for various hormone-sensitive conditions

FDA-approved peptides have a defined safety and efficacy profile for their approved indications. They are manufactured under regulated conditions with batch testing and quality accountability.

Compounded Peptides

Compounding pharmacies can legally prepare medications, including peptides, when a licensed physician writes a prescription for a patient with a specific need that cannot be met by an approved commercial product. This is legitimate medical practice.

However, compounded products are not subject to the same pre-market review as FDA-approved drugs. The FDA does not review compounding pharmacy products for efficacy or safety before they reach patients. Quality control depends entirely on the pharmacy's practices and oversight.

BPC-157, sermorelin, ipamorelin, and CJC-1295 are examples of peptides obtainable through licensed compounding pharmacies under physician prescription. Quality among compounders varies significantly. Choosing a pharmacy that follows USP 797 sterile compounding standards and has third-party batch testing is the minimum acceptable standard, not a premium option.

An important regulatory note: a compounding pharmacy cannot legally reproduce a commercially available FDA-approved drug that is not on shortage for commercial purposes. When compounded semaglutide became widespread during brand-name shortages, it operated within a specific regulatory window. That window has changed as the FDA's shortage designations have changed.

Research-Use-Only (RUO) Compounds

This is the category that generates the most confusion and the most risk. Research chemicals are compounds sold legally for laboratory research purposes, explicitly labeled not for human use. They are not manufactured to pharmaceutical standards. They have no sterility guarantee. They have no verified concentration or purity.

When someone orders a research peptide online and self-administers it, they are using a compound with no quality controls, no dosing guidance from human trials, and no physician oversight. Contamination, inaccurate concentration, and undisclosed additives are documented problems in this market, not theoretical ones.

The Gray Market Problem

The most significant regulatory concern in the current environment is the gray market: peptides sold to consumers under the implicit understanding that they will be used by humans, despite being labeled "not for human use." This market has grown in direct proportion to public interest in peptide therapy.

The FDA has increased enforcement activity around this space, particularly for compounded semaglutide and BPC-157. The practical effect is that patients sourcing from gray-market suppliers have no regulatory protection if the product is contaminated, mislabeled, or incorrectly concentrated.

What This Means for Patients

If you are considering peptide therapy, the questions to ask are:

• What is the regulatory status of this specific compound?
• Is it coming from a licensed, accredited compounding pharmacy or a research chemical supplier?
• Does the prescribing physician have a clear clinical rationale and a monitoring plan?
• What quality certifications does the compounding pharmacy hold, and is third-party batch testing available?

If those questions cannot be answered clearly, the sourcing is not appropriate for clinical use.

The seven specific red flags to watch for are covered here: 7 Red Flags When Buying Peptides Online

At Diab Longevity, every peptide used in a protocol is sourced from licensed compounders with verified quality standards. Physician oversight is not optional. Neither is tracking outcomes.

Start Your Optimization Review.

*Medical disclaimer: This content is educational and does not constitute medical advice. Regulatory information is current as of 2026 and may be subject to change. All protocols are individualized and supervised by a licensed physician.*